Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024)
Beta Bionics (BBNX) posted Preferred Stock Liabilities of $321.4 million for Q4 2024, up 22.8% sequentially from $261.7 million in Q3 2024, and up 22.8% YoY from $261.7 million in Q1 2024.
Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Beta Bionics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $321.4 million in Q4 2024.
- Quarterly Preferred Stock Liabilities rose 22.8% year-over-year to $321.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $321.4 million (up 22.8% YoY) and the FY2024 annual result came in at $321.4 million, up 22.8% from the prior year.
- Preferred Stock Liabilities rose to $321.4 million in Q4 2024 per BBNX's latest filing, from $261.7 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $321.4 million in Q4 2024 and troughed at $261.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | - |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | - |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | - |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | - |
| 10 | Beta Bionics | 853.71 Mn | 673.22 Mn | 18.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 321.37 Mn |
| Sep 30, 2024 | 261.71 Mn |
| Jun 30, 2024 | 261.71 Mn |
| Mar 31, 2024 | 261.71 Mn |
| Dec 31, 2023 | 261.71 Mn |